concur with published sequence data, with the exception of nt 1309 in MYH11. In our sequence this is a cytosine rather than the published thymine. 8 Using our patient's sequence to search GenBank we identified an unpublished sequence for the human smooth muscle myosin heavy chain gene with cytosine at nt 1309 (GenBank Accession Number X69292, submitted by K Okajima). This alternative sequence does not alter the leucine amino acid encoded at this position, and therefore may represent a polymorphism, although a PCR artefact has not been excluded, and heritability of cytosine at nt 1309 has not yet been demonstrated.
Prior exposure to DNA-topoisomerase II inhibitors has been identified as a risk factor for therapy-related AML (t-AML) associated with balanced translocations involving chromosome band 11q23, band 21q22, inv(16), t(15;17) and t(9;22). 9 In addition, it has been suggested that the less common forms of CBFB-MYH11 fusions are disproportionately represented in t-AML, particularly those following treatment with DNA-topoisomerase II inhibitors. 10 However, prior therapy with cytotoxic agents of any type was not a factor in our patient.
Identification of this novel transcript further emphasises the heterogeneity of breakpoints in the CBFB-MYH11 rearrangement and it will be interesting to determine if there is any prognostic significance associated with this and other types of CBFB-MYH11 fusion transcript. Although our patient failed to achieve complete remission, other factors such as age, concurrent medical problems, suboptimal chemotherapy and possible pre-existing myelodysplasia preclude drawing any conclusions about the impact of the unusual breakpoint on his response to treatment. 
NSW, Australia
Histologic diagnosis and precocious treatment in a case of isolated promyelocytic sarcoma TO THE EDITOR Granulocytic sarcoma (GS) is a rare extramedullary aggregate of malignant myeloid progenitor cells. Most cases of GS occur as a precursor to blast crisis in myeloproliferative and myelodysplastic syndromes or during the course of active acute myelogenous leukemia. 1 Less commonly GS represents the presenting feature of a still undiagnosed myelogenous leukemia and on rare occasions, it develops in healthy subjects, without concomitant blood or marrow evidence of hematologic disease. 2 GS is associated with every FAB leukemia subclass but it seldom arises in the course of an acute promyelocytic leukemia (APL: M3).
We recently observed a patient affected with multiple promyelocytic sarcomas in the absence of blood and marrow evidence of leukemia. He was referred to our institution complaining of mild fever (37.5-38°C) and severe chest pain. Physical examination revealed shortness of breath, pleural rubbing and the presence of two green, painless and slowly growing masses in the fronto-parietal scalp and in the lumbar region, respectively. No lymph node was palpable. A thorax and abdomen computed tomography revealed pleural thickening involving the posterior region of the 8th left rib with lytic lesions of the bone; a skull X-ray evidenced a 4 × 3 cm subcutaneous mass overlying the midline portion of the frontal bone without neural extension. An open incisional biopsy of the subcutaneous lumbar lesion revealed a green gelatinous mass histologically consistent with promyelocytic sarcoma. Immunohistochemical analysis confirmed the poorly differentiated myeloid nature of sarcoma cells with chloroacetate esterase, myeloperoxidase and CD43 being positive and with CD15 and UCHL1 negative. Full blood count was normal; blood smear and bone marrow examination showed no morphologic sign of acute myeloid leukemia (AML) while bone marrow cytogenetic examination by reverse-transcriptase polymerase chain reaction (RT-PCR) evidenced the bcr1 type of the typical PML-RARA fusion transcript. 4 All patients with isolated GS either die shortly after the diagnosis or, in most cases, eventually develop leukemia. 2, 5 Aggressive combination chemotherapy at the time of diagnosis is the only treatment able to prolong life and prevent the subsequent development of leukemia. 5 Our patient was treated with systemic chemotherapy according to the GIMEMA protocol 6 obtaining both complete remission of the promyelocytic sarcomas and the disappearance of the genetic PML-RARA rearrangement in two consecutive bone marrow aspirates; after this therapy, a bone marrow harvest was performed in case of an eventual transplantation. Thirteen months from diagnosis, the patient shows no sign of AML or sarcoma relapse.
The isolated GS often represents a diagnostic dilemma for both the clinician and the pathologist; as a matter of fact, more than 75% of GS are initially misdiagnosed as other neoplasms, mainly as malignant lymphomas, 3 and a correct diagnosis is often made only when lesions recur or leukemia develops. 2 In our case the morphologic and immunohistochemical analysis of the lesion, the molecular findings in the bone marrow together with the response to therapy strongly suggest that GS was infiltrated by leukemic promyelocytes. As far as we are aware, the histologic diagnosis of isolated promyelocytic sarcoma has never been described before. As a matter of fact, in two previously reported cases, a GS was radiologically identified, but not histologically diagnosed, in non-leukemic patients who subsequently developed APL; in both cases histologic diagnosis was made by bone marrow examination after APL development only. 7, 8 More recently, Tosi et al vivors.
1,2 Here we report a pediatric case of MDS with unbalanced t(1;7) (q10;p10) after SAA treated with cyclosporin A (CsA) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). A 1-year-old boy was diagnosed with idiopathic SAA. On admission, the karyotype of BM cells were 46,XY. He was treated with CsA and rhG-CSF. This therapy was continued until complete hematological recovery was obtained (CsA for 29 months and rhG-CSF for 20 months). The total administered dose of rhG-CSF was 17 150 g/body. Two months after cessation of CsA, the patient demonstrated recurrent pancytopenia. At that time, BM showed dysplasia of erythroid and myeloid lineage cells and micromegakaryocytes
